Market Overview

UPDATE: Citigroup Initiates Jazz Pharmaceuticals at Buy; Expecting Settlement to Remove Overhang

Related JAZZ
Benzinga's Top Downgrades
Earnings Scheduled For November 9, 2015
Don't Forget Hot Sectors When Looking For New Stocks (Investor's Business Daily)

Citigroup initiated coverage on Jazz Pharmaceuticals (NASDAQ: JAZZ) with a Buy rating and a $70 price target.

Citigroup commented, "We see a high probability (~≥75%) of either a settlement or win for JAZZ around the ongoing litigation with Roxane over narcolepsy drug Xyrem. While we believe JAZZ currently has the upper hand to win the suit, a settlement would be strategic for both parties and either outcome would lift the overhang for JAZZ's valuation. A loss for JAZZ could push its valuation as far down as the low $30's, but we are establishing a $70 TP assuming a favorable outcome for JAZZ (settlement or win) and view the most probable settlement window from late Dec. `12 - Jun `13."

Jazz Pharmaceuticals closed at $51.85 on Monday.

Latest Ratings for JAZZ

Nov 2015BernsteinInitiates Coverage onMarket Perform
Nov 2015Mizuho SecuritiesDowngradesOutperformNeutral
Nov 2015Leerink SwannMaintainsOutperform

View More Analyst Ratings for JAZZ
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Initiation Intraday Update Analyst Ratings


Related Articles (JAZZ)

Get Benzinga's Newsletters